Abstract 1839P
Background
Taxanes are a standard of care for mCRPC and no clinically qualified biomarker has as yet been identified for these. lpWGS of ctDNA identifies copy-number alterations (CNAs) common in advanced PC and may identify mCRPC subtypes most responsive to taxane therapy. ctDNA lpWGS identified genomic aberrations associating with treatment outcomes for participants of three prospective Phase III taxane trials (CARD, FIRSTANA and PROSELICA).
Methods
Genomic alterations in ctDNA were assessed for correlations with overall survival (OS), radiologic progression-free survival (rPFS), and PSA or radiological response rate (RR) using univariable and multivariable mixed-effect regression models to study CNAs significantly associated with differential outcomes of prognostic and predictive significance.
Results
Genome-wide analysis identified several genomic alterations that were significantly associated with worse OS in these taxane-treated individuals including chromosome 2p, 9p and 13 deletions. Several CNAs remained independently significant (Chr2p HR 2.89, p<0.01; Chr9p HR 2.9, p<0.01, Chr12q HR 2.06, p<0.01) following multivariable analyses incorporating PSA, LDH, haemoglobin, the presence of visceral metastases and tumour fraction estimate. Conversely, several loci including 20q and X gain, and 15q loss associated with worse rPFS and OS on the CARD control arm (abiraterone post enzalutamide or vice versa) but exhibited no difference in rPFS and OS on the cabazitaxel-treated arm. To confirm these results, we explored the association of CNAs with response rate in the FIRSTANA and PROSELICA study cohorts and found that several loci were associated with higher taxane-response rates in biomarker-positive individuals.
Conclusions
These ctDNA lpWGS studies in mCRPC patients have identified genomic alterations in ctDNA of prognostic and predictive significance in men suffering from mCRPC receiving taxane treatment. Prospective validation will facilitate treatment selection and identify potential clinical biomarkers associated with outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Institute of Cancer Research.
Funding
Sanofi Aventis; Prostate Cancer UK.
Disclosure
N. Mehra: Financial Interests, Personal, Advisory Board: Pfizer, Roche, MSD, AstraZeneca, Astellas, JNJ; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Funding: Astellas, Pfizer; Financial Interests, Personal and Institutional, Funding: Janssen; Financial Interests, Institutional, Coordinating PI: BMS, Janssen, BMS; Financial Interests, Institutional, Research Grant: AstraZeneca, BMS; Non-Financial Interests, Leadership Role, Head of the Prostate Cancer Working group: Dutch Uro-Oncology Study Group; Non-Financial Interests, Principal Investigator, co-PI: Prospective Bladder Cancer Infrastructure (Netherlands); Non-Financial Interests, Leadership Role: Castration-resistant Prostate Cancer Registry. M. Eisenberger: Financial Interests, Personal, Member of Board of Directors: VERU Inc; Financial Interests, Personal, Stocks/Shares: VERU Inc; Financial Interests, Personal, Advisory Board: Merck, Seagen, BMS. K. Fizazi: Financial Interests, Institutional, Advisory Board: Astellas, Bayer, Janssen, AAA, MSD, AstraZeneca, Novartis/AAA, Pfizer, Daiichi Sankyo; Financial Interests, Institutional, Invited Speaker: Astellas, Bayer, Janssen, Sanofi, MSD, AstraZeneca, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Curevac, Orion; Financial Interests, Personal, Advisory Board, February 2022: Arvinas; Financial Interests, Personal, Advisory Board, April 2022: Macrogenics; Financial Interests, Institutional, Research Grant, Trial chair: Pfizer, Bayer, AstraZeneca, Orion, MSD, BMS, Janssen; Non-Financial Interests, Principal Investigator, Chair of the 7DX phase 3 trial: BMS; Non-Financial Interests, Principal Investigator, Chair of the Docetaxel-pembrolizumab phase 3 trial: Merck; Non-Financial Interests, Principal Investigator, Chair of the Darolutamide BCR phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the PSMAfore phase 3 trial: AAA/Novartis; Non-Financial Interests, Principal Investigator, Chair of the CYPIDES ODM-208 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the STESIDES ODM-209 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the CAPITELLO 281 phase 3 trial: AstraZeneca; Non-Financial Interests, Principal Investigator, Chair of the TALAPRO-2 and TALAPRO-3 phase 3 trials: Pfizer; Non-Financial Interests, Principal Investigator, Chair of the RADIANT phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the TRITON-3 phase 3 trial: Clovis. B. Tombal: Financial Interests, Personal, Advisory Board: Astellas, Bayer, Amgen, Janssen, Sanofi, Myovant, Novartis (AAA), Pfizer, Astellas, MSD, AstraZeneca; Financial Interests, Personal, Invited Speaker: Astellas, Amgen, Ferring; Non-Financial Interests, Member of Board of Directors, Past President: European Organisation of Research and Treatment of Cancer (EORTC); Non-Financial Interests, Member of Board of Directors, Education in the field of Oncology: ISSECAM. C.N. Sternberg: Financial Interests, Personal, Advisory Board, AD board and speaker at ESMO: Pfizer; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, Astellas, Sanofi-Genzyme, Roche-Genentech, Foundation Medicine, Immunomedics, Janssen; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Advisory Board, Was the head if the oversignt committee, of Phase III trial but last meeting over 1 year ago: Seattle Genetics; Financial Interests, Personal, Other, AD board: BMS; Financial Interests, Personal, Other, Speaker, owned by Prostate Cancer Foundation: Uro Today; Financial Interests, Personal, Other, Speaker, CME activities: Medscape. D.E. Castellano Gauna: Financial Interests, Personal, Advisory Board: Pfizer, Roche, BMS, Janssen, Astellas, MSD, Ipsen, AstraZeneca Novartis, GSK; Financial Interests, Institutional, Local PI: Pfizer, Roche, MSD, BMS, AstraZeneca Janssen, Astellas, Ipsen, Exelisis, Eisai, Lilly, Bayer, GSK, CLOVIS, QED Therapeutics; Non-Financial Interests, Personal, Other, Executive member: SOGUG (Spanish Oncology Genito-Urinary Group) Foundation. S. Oudard: Financial Interests, Personal, Speaker, Consultant, Advisor, honoraria, travel expenses: AstraZeneca, Astellas, BMS, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi, Bayer; Financial Interests, Personal, Advisory Board, travel expenses: Roche. O. Sartor: Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: AstraZeneca, Bayer, Janssen; Financial Interests, Personal, Speaker, Consultant, Advisor: Clovis Oncology, Invitae, Pfizer. C. Geffriaud-Ricouard: Financial Interests, Personal, Full or part-time Employment, I am a full time employee at Sanofi (global medical lead): Sanofi. M. Chadjaa: Financial Interests, Personal, Full or part-time Employment: Sanofi; Financial Interests, Personal, Stocks/Shares: Sanofi. S. Mace: Financial Interests, Personal, Full or part-time Employment: Sanofi. J.S. de Bono: Financial Interests, Personal, Advisory Board: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Menarini Silicon Biosystems, ImCheck Therapeutics, Crescendo; Financial Interests, Institutional, Advisory Board: Harpoon; Financial Interests, Institutional, Research Grant: Astellas, AstraZeneca, Bayer, Cellcentric, Daiichi Sankyo, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Sanofi Aventis, Sierra Oncology, Taiho, Vertex Pharmaceuticals, Crescendo Biologics, Menarini Silicon Biosystems; Non-Financial Interests, Principal Investigator: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Menarini Silicon Biosystems, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Crescendo, ImCheck Therapeutics; Non-Financial Interests, Institutional, Product Samples: Daiichi Sankyo, Bayer, Merck Serono, AstraZeneca, Harpoon, Pfizer, Sierra Oncology, Genentech/Roche, Sanofi Aventis, GSK. All other authors have declared no conflicts of interest.
Resources from the same session
1971P - Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: Mathilde Reich
Session: Poster session 15
1972P - Molecular mechanism study of recurrence/metastasis for Enneking IIb osteosarcoma
Presenter: Junqiang Yin
Session: Poster session 15
1975P - Systemic therapy for KIT/PDGFRA wild-type GIST
Presenter: Mehdi Brahmi
Session: Poster session 15
1976P - Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Presenter: Deborah van de Wal
Session: Poster session 15
1977P - A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Presenter: Jerry Call
Session: Poster session 15
1978P - Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
Presenter: Denisse Evans
Session: Poster session 15
1979P - phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Presenter: Kathryn Lurain
Session: Poster session 15
1980P - Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Presenter: Sant Chawla
Session: Poster session 15
1981P - Histopathological diagnostic discrepancies in bone and soft tissue tumors referred to a specialist sarcoma center and its clinical impact
Presenter: Akira Kawai
Session: Poster session 15